![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Stanford University |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00523185 |
The purpose of this study is to compare the efficacy of two commonly used medications in the treatment of alcohol withdrawal, diazepam and lorazepam.
Condition | Intervention |
---|---|
Alcohol Withdrawal |
Drug: Lorazepam Drug: Diazepam |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal |
Enrollment: | 55 |
Study Start Date: | May 2003 |
Study Completion Date: | November 2004 |
Arms | Assigned Interventions |
---|---|
2: Active Comparator |
Drug: Diazepam
Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
|
1: Active Comparator |
Drug: Lorazepam
Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
|
Despite the frequent use of benzodiazepines for the treatment of alcohol withdrawal, studies comparing the efficacy of long and short half-life benzodiazepines in the treatment of alcohol withdrawal have shown mixed results. Due to the conflicting nature of published reports, clinicians have no clear indication as to which type of agent is preferable. The purpose of this study is to compare the efficacy of two commonly accepted medications in the treatment of alcohol withdrawal, diazepam and lorazepam, which are long and short half-life benzodiazepines, respectively.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Stanford Hospital and Clinics | |
Stanford, California, United States, 94305 | |
Palo Alto Veterans Affairs Hospital System | |
Palo Alto, California, United States, 94304 |
Principal Investigator: | Jose R Maldonado, MD | Stanford University |
Study ID Numbers: | 77757 |
Study First Received: | August 29, 2007 |
Last Updated: | August 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00523185 |
Health Authority: | United States: Institutional Review Board |
alcohol withdrawal lorazepam diazepam |
Lorazepam Diazepam Ethanol |
Anesthetics, Intravenous Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Gastrointestinal Agents Anesthetics Antiemetics Central Nervous System Depressants Neuromuscular Agents |
Pharmacologic Actions Adjuvants, Anesthesia Anesthetics, General Autonomic Agents Therapeutic Uses Muscle Relaxants, Central Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants |